The PoNS device led to sustained benefits in gait function in people with multiple sclerosis in a real-world study.

The menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women, accordi ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

Researchers identified a key protein as a potential therapeutic target for stopping the body's immune system from mistakenly attacking itself, offering new hope for treating autoimmune diseases and ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

Mothers with multiple sclerosis (MS) have an elevated incidence and prevalence of peripartum mental illness, according to a study published online Jan. 22 in Neurology. Ruth Ann Marrie, M.D., from ...

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other chronic conditions, according to a new study analyzing over 890,000 births ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...